Affiliation:
1. Pharmacy Department, The Second Affiliated Hospital, Zhejiang Chinese Medical University, China
2. HD Biosciences (A WuXi company) Pharma Tech, Shanghai 201201, China
Abstract
Background::
Astragali Radix (AR) has a long history as a traditional Chinese medicine
for anti-osteoporosis (OP) treatment. The aim of the study was to explore the effect and optimal
regimens of AR and its main ingredients (IAR) in OP treatment.
Methods::
Eligible animal studies were searched in seven databases (PubMed, Web of Science,
MEDLINE, SciELO Citation Index, Cochrane Library, China National Knowledge Infrastructure
and Wanfang). The primary outcomes were bone metabolic indices. The secondary outcome measure
was the anti-OP mechanism of IAR.
Results::
21 studies were enrolled in the study. The primary findings of the present article illustrated
that IAR could significantly increase the bone mineral density (BMD), bone volume over the total
volume, trabecular number, trabecular thickness, bone maximum load and serum calcium,
while trabecular separation and serum C-terminal telopeptide of type 1 collagen were remarkably
decreased (P < 0.05). In subgroup analysis, the BMD in the long treatment group (≥ 10 weeks)
showed better effect size than the short treatment group (< 10 weeks) (P < 0.05). Modeling methods
and animal sex were factors affecting serum alkaline phosphatase and osteocalcin levels.
Conclusion::
The findings suggest the possibility of developing IAR as a drug for the treatment of
OP. IAR with longer treatment time may achieve better effects regardless of animal strain and
age.
Funder
Natural Science Foundation of Zhejiang Province
Zhejiang Provincial Health Science and Technology Plan Project
Zhejiang Traditional Chinese Medicine Science and Technology Plan Project
Publisher
Bentham Science Publishers Ltd.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献